Cargando…

PM287. Mixtures of opioid receptor agonists and cannabinoid receptor agonists: enhanced antinociception without abuse liability

Detalles Bibliográficos
Autores principales:	France, Charles P, Maguire, David R, Minervini, Vanessa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616223/ http://dx.doi.org/10.1093/ijnp/pyw041.287

Ejemplares similares

Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966
por: Reichenbach, Zachary W., et al.
Publicado: (2022)

Assessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176
por: Tampus, Reinholdgher, et al.
Publicado: (2015)

Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB(2) receptor agonist ABK5
por: Tang, Yaliang, et al.
Publicado: (2020)

Probing the Activation Mechanisms of Agonist DPI-287 to Delta-Opioid Receptor and Novel Agonists Using Ensemble-Based Virtual Screening with Molecular Dynamics Simulations
por: Dean, Emily, et al.
Publicado: (2023)

In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
por: Guillemyn, Karel, et al.
Publicado: (2012)

Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance
por: Mosberg, Henry I., et al.
Publicado: (2014)

The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception
por: Hill, Rob, et al.
Publicado: (2018)

PM432. Evaluation of the extrapyramidal side effects (EPS) liability of NMDA receptor glycine-binding site agonists
por: Ohno, Yukihiro, et al.
Publicado: (2016)

Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018
por: Finlay, David B., et al.
Publicado: (2022)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

Antinociceptive activity of the S1P-receptor agonist FTY720
por: Coste, Ovidiu, et al.
Publicado: (2008)

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB(2) receptor
por: Patel, Monica, et al.
Publicado: (2023)

The Hypnotic, Anxiolytic, and Antinociceptive Profile of a Novel µ-Opioid Agonist
por: Montes, Guilherme Carneiro, et al.
Publicado: (2017)

Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain
por: Yuill, Matthew B, et al.
Publicado: (2017)

Antinociceptive and Abuse Potential Effects of Cannabinoid/Opioid Combinations in a Chronic Pain Model in Rats
por: Alsalem, Mohammad, et al.
Publicado: (2019)

Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism
por: Gavryushov, Sergei, et al.
Publicado: (2023)

Modulation of G-protein activation, calcium currents and opioid receptor phosphorylation by the pH-dependent antinociceptive agonist NFEPP
por: Celik, Melih Özgür, et al.
Publicado: (2023)

Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
por: Takheaw, Nuchjira, et al.
Publicado: (2023)

Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone
por: Michaelides, Michael, et al.
Publicado: (2023)

5-Benzyl substituted 14-methoxymetopon, a high affinity μ opioid receptor agonist with potent antinociceptive activity in mice
por: Spetea, Mariana, et al.
Publicado: (2008)

Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
por: Mititelu Tartau, Liliana, et al.
Publicado: (2021)

Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
por: Wang, Xin, et al.
Publicado: (2021)

Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist
por: Taylor, A M W, et al.
Publicado: (2015)

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
por: Levy-Cooperman, N., et al.
Publicado: (2016)

Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users
por: Shram, Megan J., et al.
Publicado: (2021)

Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists
por: Azevedo Neto, Joaquim, et al.
Publicado: (2021)

Comparative antinociceptive effect of arachidonylcyclopropylamide, a cannabinoid 1 receptor agonist & lignocaine, a local anaesthetic agent, following direct intrawound administration in rats
por: Kumar, Rahul, et al.
Publicado: (2016)

Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting
por: May, Benedict, et al.
Publicado: (2019)

New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists
por: Faúndez-Parraguez, Manuel, et al.
Publicado: (2021)

Docking and Molecular Dynamic Investigations of Phenylspirodrimanes as Cannabinoid Receptor-2 Agonists
por: Omar, Abdelsattar M., et al.
Publicado: (2022)

Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor
por: Zagzoog, Ayat, et al.
Publicado: (2021)

Role of mu opioid receptor (MOR) agonist efficacy as a determinant of opioid antinociception in a novel assay of pain-depressed behavior in female and male mice
por: Negus, S. Stevens, et al.
Publicado: (2023)

Novel Mixed NOP/Opioid Receptor Peptide Agonists
por: Pacifico, Salvatore, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
por: Bornebusch, Annika Billefeld, et al.
Publicado: (2019)

Fluoroscopic Characterization of Colonic Dysmotility Associated to Opioid and Cannabinoid Agonists in Conscious Rats
por: Díaz-Ruano, Susana, et al.
Publicado: (2019)

KCC2 receptor upregulation potentiates antinociceptive effect of GABAAR agonist on remifentanil-induced hyperalgesia
por: Gao, Yuan, et al.
Publicado: (2022)

Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex
por: Diez-Alarcia, Rebeca, et al.
Publicado: (2016)

Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists
por: Sachdev, Shivani, et al.
Publicado: (2020)

Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights
por: Malaca, Sara, et al.
Publicado: (2021)

A2 ACUTE COLITIS CAUSES CHANGES TO THE EFFICACY OF CANNABINOID-1 AND MU-OPIOID RECEPTOR AGONISTS ON INHIBITING ABDOMINAL PAIN
por: Tsang, Q K, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vikstddrtq11djj79pn1eo20bl